Day: May 11, 2020
FDA Approves Tabrecta, First Targeted Therapy for NSCLC
The FDA has approved Tabrecta, Novartis for the treatment of non-small cell lung cancer (NSCLC) that has spread to other parts of the body. NSCLC is the most [...]